Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9540132 | 0.85 | SCN9A (0.54) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL16109588 | 0.85 | SCN9A (0.56) | SCN9ACMA1MMP12ADAMTS5L3MBTL1 | |
| SCHEMBL9539012 | 0.84 | OPRL1 (0.51) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL17377477 | 0.81 | SCN9A (0.63) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL1773322 | 0.80 | CMA1 (0.60) | CMA1L3MBTL1GSK3AGSK3BMAPT | |
| SCHEMBL25430199 | 0.80 | SCN9A (0.65) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL17416402 | 0.76 | OPRL1 (0.70) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL16812434 | 0.76 | OPRL1 (0.60) | SCN9ACMA1OPRL1MMP12ADAMTS5 | |
| SCHEMBL15973283 | 0.76 | SCN9A (0.51) | SCN9ACMA1MMP12ADAMTS5GSK3A | |
| SCHEMBL8552517 | 0.76 | SCN9A (0.54) | SCN9ACMA1OPRL1MMP12ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214676-B2 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070049558-A1 | New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | PFIZER INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049558-A1 | New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | PDE3A, PDE4A, PDE5A | SCN9A 1450/4885CMA1 1667/4885OPRL1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.